Dr. Jérémie Calais from the University of California, Los Angeles discusses the first annual PSMA Conference as well as new updates in the field of PSMA-RLT.
Dr. Jérémie Calais Discusses PSMA-RLT and the 2024 PSMA Conference
By Jérémie Calais, MD, PhD - Last Updated: January 24, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.